The World Health Organization’s Covax is feeling the strain from COVID-19 vaccine shortages; Argentina faces a new lockdown following a surge of COVID-19 cases; leronlimab ineffective against COVID-19.
A collaboration from the World Health Organization (WHO); Gavi, the Vaccine Alliance; and the Coalition for Epidemic Preparedness Innovations, Covax may be unable to meet its goal of supplying 20% of populations from the world’s 92 poorest countries with free COVID-19 vaccine doses by year-end as promised. Reported by The Wall Street Journal, despite deals with Pfizer, Moderna, Johnson & Johnson, and Novavax, Covax’s main supplier in India, the Serum Institute, is unable to export any doses at present, having been blocked by that country’s government, which wants to focus on vaccinating its citizens as it endures a surge of the deadly virus.
New coronavirus infections have topped 35,000 for 3 straight days in Argentina, accompanied by a skyrocketing number of deaths, reports The Associated Press. On Tuesday alone, there were 745 deaths and 35,543 new cases, breaking the nation’s previous daily records for both. The current lockdown will last through May 31, with President Alberto Fernández promising economic aid to areas affected by these new restrictions, as well as 4 million doses of the AstraZeneca and Sputnik V vaccines.
The monoclonal antibody leronlimab, from CytoDyn, failed to meet its primary end point or any of its secondary end points in 2 trials—CD10 and CD12—prompting the FDA to note that “data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19.” Data from CD10 show no difference in symptom resolution between the study and placebo groups, meaning both saw symptoms resolve no matter which agent they received, whereas in CD12 mortality rates from both groups were close to equal, at 20.5% in the leronlimab group and 21.6% in the placebo group.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen